profit from every $100 of sales.
$0$100
Scholar Rock
$46.60-2.92% today
+51.3% in 1 year
1-year low $30.071-year high $60.04
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2019 to 2022.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Scholar Rock sold, what it kept, and what it did with the cash.
Sales went from $33.2 million in 2022 to $0 in 2025, with -$378 million of profit last year.
SalesProfit
Scholar Rock vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Scholar Rock | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Scholar Rock's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 15 | 19 | 33 | 0 | 0 | 0 | |
| – | – | – | – | – | – | |
| -87 | -130 | -134 | -171 | -252 | -385 | |
| -85 | -127 | -131 | -168 | -238 | -369 | |
| -86 | -132 | -135 | -166 | -246 | -378 | |
| -2.81 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | |
| – | – | – | – | – | – | |
| -564.0% | -690.5% | -404.8% | – | – | – | |
| -561.5% | -700.5% | -405.2% | – | – | – |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 388 | 304 | 358 | 311 | 475 | 404 |
| Cash | 160 | 213 | 103 | 102 | 178 | 324 |
| Total debt | 57 | 77 | 69 | 62 | 65 | 109 |
| Total liabilities | 128 | 132 | 98 | 86 | 106 | 159 |
| 261 | 172 | 260 | 225 | 369 | 245 | |
| 31 | 37 | 60 | 83 | 100 | 115 | |
| -21.6% | -41.2% | -32.2% | -47.1% | -43.6% | -82.7% | |
| -33.2% | -76.6% | -51.7% | -73.6% | -66.8% | -154.0% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -60 | -127 | -133 | -145 | -201 | -300 | |
| 4 | 5 | 1 | 0 | 0 | 1 | |
| -64 | -132 | -134 | -145 | -201 | -301 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 11 | 23 | 28 | 27 | 37 | 76 |
Valuation
- –
- –
- –
- 22.8×
- 171.3×
- –
- –
- -2.4%
- -2.4%
- 0.0%
Profitability
- 0.0%
- -404.8%
- -405.2%
- 0.0%
- -85.0%
- -62.7%
- -163.5%
- -76.4%
- -86.1%
- –
Growth
- +17.4%
- –
- −49.5%
- –
- +33.0%
Financial health
- -0.3×
- 0.75
- 38.4%
- -55.5×
- 8.64
- 8.64
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 959
Top 32%of 889
Bottom 27%of 987
What analysts expect
- Average price target
- $56.57
- Range
- $50.00 – $62.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.83 | -0.82 | −1.2% |
| Mar 3, 2026 | -0.88 | -0.88 | +0.3% |
| Nov 14, 2025 | -0.90 | -0.84 | −7.8% |
| Aug 6, 2025 | -0.98 | -0.66 | −48.5% |
| May 14, 2025 | -0.67 | -0.63 | −6.3% |
| Feb 27, 2025 | -0.60 | -0.60 | +0.0% |
| Nov 12, 2024 | -0.66 | -0.58 | −13.8% |
| Aug 8, 2024 | -0.60 | -0.61 | +1.6% |
News
This retired professor has reinvented himself — as a Taylor Swift scholarMarketWatch · Nov 9, 2026Scholar Rock Q3 2026 Earnings PreviewSeeking Alpha · Nov 9, 2026Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophySeeking Alpha · Sep 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
35No pass
Philip Fisher
34No pass
Peter Lynch
51No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
31No pass
Questions about Scholar Rock
Is Scholar Rock a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Scholar Rock AI analysis
What does Scholar Rock do?
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. It is in Biotechnology, based in Cambridge, MA, United States, with 289 employees.
Does Scholar Rock pay a dividend?
No. Scholar Rock does not pay a dividend at the moment.
Is Scholar Rock stock halal?
Yes. Scholar Rock passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Scholar Rock stock done over the past year?
Up 51.3% over the past twelve months, to $46.60. It traded between $30.07 and $60.04 and is 22.4% below its high.
Who are Scholar Rock's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Scholar Rock's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.